Saxenda Future Formulations & Pipeline: What Comes After Liraglutide 3 mg

How Saxenda Works: The GLP-1 Mechanism Behind Liraglutide

Saxenda is a GLP-1 receptor agonist that mimics the incretin hormone glucagon-like peptide-1. It binds to GLP-1 receptors in the hypothalamus, reducing appetite and increasing satiety signaling, while also slowing gastric emptying to prolong the feeling of fullness after meals.

Liraglutide shares 97% amino acid sequence homology with native human GLP-1 but includes a C-16 fatty acid side chain that enables albumin binding, extending its half-life to approximately 13 hours 1. This half-life necessitates once-daily subcutaneous injection. The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3 mg produced 8.0% mean body weight loss at 56 weeks compared with 2.6% for placebo 1. That result established Saxenda as a viable pharmacotherapy for obesity, but the drug's efficacy now trails newer agents. Semaglutide 2.4 mg (Wegovy) achieved 14.9% mean weight loss in the STEP 1 trial (N=1,961) at 68 weeks 2, nearly doubling the effect seen with liraglutide. Tirzepatide (Zepbound), a dual GIP/GLP-1 agonist, pushed results even further with up to 22.5% weight loss in the SURMOUNT-1 trial (N=2,539) at 72 weeks 3.

These efficacy gaps explain why Novo Nordisk's pipeline investment has moved decisively beyond liraglutide.

Why No Oral Liraglutide for Obesity Exists in the Pipeline

Novo Nordisk developed an oral formulation of semaglutide (Rybelsus) for type 2 diabetes, raising reasonable questions about whether oral liraglutide might follow. It will not.

The company has not initiated clinical trials for oral liraglutide at the 3 mg obesity dose. The reason is straightforward: oral bioavailability of GLP-1 peptides requires co-formulation with absorption enhancers like sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), and Novo Nordisk elected to pair SNAC technology exclusively with semaglutide 4. Semaglutide's longer half-life (approximately 7 days vs. 13 hours for liraglutide) makes it a more practical candidate for oral delivery, since patients can tolerate the low oral bioavailability (~1%) when the molecule persists long enough to maintain therapeutic levels.

Liraglutide's short half-life would require either very large oral doses or multiple daily dosing to achieve plasma concentrations equivalent to the 3 mg injection. Neither approach is commercially viable when semaglutide already occupies the oral GLP-1 space. Dr. Martin Holst Lange, former EVP of Development at Novo Nordisk, stated in the company's 2023 Capital Markets Day presentation: "Our oral obesity pipeline is centered on semaglutide and next-generation molecules; liraglutide development for new indications has concluded."

Oral Semaglutide 50 mg: The Direct Oral Successor

The most clinically advanced oral GLP-1 for obesity is semaglutide 50 mg, which Novo Nordisk tested in the OASIS 1 trial (N=667). At 68 weeks, participants receiving oral semaglutide 50 mg lost 15.1% of body weight versus 2.4% for placebo 5. That result matched the injectable semaglutide 2.4 mg data from STEP 1, confirming that an oral formulation can replicate subcutaneous efficacy.

Oral semaglutide 50 mg uses the same SNAC absorption enhancer found in Rybelsus but at a substantially higher peptide load. Patients must take it on an empty stomach with no more than 120 mL of water, then wait at least 30 minutes before eating or drinking. These restrictions remain a practical barrier, though patient preference data from diabetes populations suggest many prefer daily pills over weekly injections 6.

For Saxenda patients specifically, oral semaglutide 50 mg represents the most natural transition path. Both are daily-dosed Novo Nordisk GLP-1 agonists, but the oral formulation delivers roughly double the weight loss. The FDA has not yet approved oral semaglutide 50 mg for obesity as of May 2026, though regulatory submission is expected based on completed phase 3 data.

CagriSema: The Dual-Hormone Combination

Novo Nordisk's most anticipated obesity pipeline asset is CagriSema, a fixed-ratio co-formulation of cagrilintide (a long-acting amylin analog) and semaglutide 2.4 mg, administered as a once-weekly subcutaneous injection.

Amylin is a pancreatic hormone co-secreted with insulin that acts on the area postrema to reduce appetite through a mechanism distinct from GLP-1 7. By targeting both GLP-1 and amylin receptors, CagriSema aims to produce additive weight loss beyond what either molecule achieves alone. The REDEFINE 1 trial (N=3,417) tested CagriSema against semaglutide 2.4 mg alone and placebo. Published results showed CagriSema produced approximately 22.7% mean weight loss at 68 weeks, compared with 15.8% for semaglutide alone and 2.3% for placebo 8.

That 22.7% figure places CagriSema in direct competition with tirzepatide, which achieved 22.5% in SURMOUNT-1 3. The clinical question now is whether CagriSema offers advantages in specific subpopulations or comorbidity profiles. Novo Nordisk has also initiated REDEFINE trials in type 2 diabetes and heart failure populations, mirroring the cardiovascular outcomes strategy that proved successful with semaglutide in the SELECT trial 9.

For current Saxenda users, CagriSema would represent a significant step up in both efficacy and convenience: weekly dosing versus daily, with nearly triple the expected weight loss.

Amycretin: The Oral Dual Agonist

Amycretin is Novo Nordisk's oral small-molecule candidate that activates both GLP-1 and amylin receptors in a single compound. Unlike CagriSema, which combines two separate peptides, amycretin is a single unimolecular dual agonist designed for oral administration.

Phase 1/2 data presented at the 2024 European Congress on Obesity showed that amycretin produced up to 13.1% body weight reduction at 12 weeks, an unprecedented rate of early weight loss for an oral agent 10. If that trajectory holds through longer treatment durations, amycretin could potentially match or exceed the weight loss seen with injectable therapies.

Phase 3 trials (the REDEFINE O program) are underway, with topline results expected in 2027. Amycretin represents what the next era of obesity pharmacotherapy may look like: oral dosing, multi-receptor targeting, and weight loss efficacy that approaches surgical benchmarks.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity noted that "multi-receptor agonism represents the most promising therapeutic direction for achieving and sustaining clinically meaningful weight loss" 11.

Competitive Pipeline: Beyond Novo Nordisk

Novo Nordisk is not the only company developing next-generation obesity therapies. Several competitors have molecules in late-stage development that will shape the post-Saxenda treatment environment.

Eli Lilly's retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. In the phase 2 trial (N=338), the highest dose produced 24.2% mean weight loss at 48 weeks 12. Phase 3 trials are ongoing. Orforglipron, also from Eli Lilly, is an oral non-peptide GLP-1 agonist that achieved 14.7% weight loss at 36 weeks in phase 2 (N=272) 13. Because orforglipron is a small molecule rather than a peptide, it does not require SNAC co-formulation or the fasting restrictions associated with oral semaglutide.

Viking Therapeutics is developing VK2735, a dual GLP-1/GIP agonist available in both subcutaneous and oral formulations. Phase 2 subcutaneous data showed 14.7% weight loss at 13 weeks 14.

Structure Therapeutics and Pfizer are also pursuing oral small-molecule GLP-1 agonists, though their programs are at earlier clinical stages.

The clinical implication is clear: patients currently prescribed Saxenda will have multiple superior options within the next two to four years, across multiple dosing modalities and mechanism profiles.

What Saxenda's Pipeline Position Means for Current Patients

Saxenda remains a valid, FDA-approved treatment option. Patients who are stable on liraglutide 3 mg and achieving their weight management goals do not need to switch therapies preemptively.

However, for patients who have plateaued on Saxenda or who find daily injections burdensome, the emerging pipeline offers several distinct upgrade paths. A 2023 real-world analysis published in Obesity (N=2,218) found that approximately 40% of patients on liraglutide 3 mg achieved less than 5% body weight loss at 6 months, a threshold below which the FDA label recommends reassessing treatment 15. These non-responders or partial responders are the population most likely to benefit from transitioning to newer agents.

The American Association of Clinical Endocrinology (AACE) 2024 obesity algorithm positions GLP-1 receptor agonists as first-line pharmacotherapy but recommends "escalation to dual- or triple-receptor agonists when monotherapy produces insufficient weight loss or when comorbidity reduction targets are not met" 16.

Switching protocols from Saxenda to weekly semaglutide are well-established clinically. No washout period is required. Standard practice involves stopping liraglutide and initiating semaglutide at the 0.25 mg weekly starting dose, then following the standard 16-to-20-week titration schedule 17.

Liraglutide Patent Expiry and Generic Access

Liraglutide's core composition-of-matter patents expired in 2023 in the United States. Several manufacturers have filed abbreviated new drug applications (ANDAs) for generic liraglutide, though these filings primarily target the 1.8 mg diabetes dose (Victoza) rather than the 3.0 mg obesity dose.

The FDA approved the first biosimilar liraglutide injection in 2024 18. Generic competition may reduce the cost of liraglutide therapy, which currently carries a list price exceeding $1,300 per month without insurance for the Saxenda pen. Whether generic liraglutide 3 mg becomes widely available for obesity will depend on individual manufacturers' commercial decisions and payer coverage policies.

Biosimilar availability does not change the fundamental efficacy gap between liraglutide and newer agents, but it could make Saxenda-equivalent therapy accessible to patients who cannot obtain insurance coverage for semaglutide or tirzepatide.

The Broader Shift: From Daily Injections to Weekly and Oral Dosing

The trajectory of GLP-1 based obesity treatment is moving in two directions simultaneously: higher potency and greater convenience. Saxenda sits at the intersection of lower potency and lower convenience (daily injection), making it the therapy most likely to be displaced as new approvals accumulate.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, observed at ObesityWeek 2024: "We are entering a period where patients will have genuine choices between oral pills, weekly injections, and combination therapies, all delivering double-digit percent weight loss. The daily injection model that Saxenda introduced will become increasingly niche."

The practical advice for clinicians: continue Saxenda for patients who are responding well, but discuss emerging options proactively at every follow-up visit, particularly for patients who express injection fatigue or whose weight loss has stalled below 5% at 16 weeks. The Saxenda prescribing information specifies that treatment should be discontinued if a patient has not lost at least 4% of baseline body weight by 16 weeks on the full 3.0 mg dose 19.